Angle PLC MD Anderson Collaboration (9429E)
February 16 2015 - 2:01AM
UK Regulatory
TIDMAGL
RNS Number : 9429E
Angle PLC
16 February 2015
For immediate release 16 February 2015
ANGLE plc
("ANGLE" or "the Company")
COLLABORATION WITH MD ANDERSON CANCER CENTER
ON COLORECTAL CANCER
ANGLE plc (AIM:AGL and OTCQX:ANPCY), the specialist medtech
company, is delighted to announce a collaboration with the MD
Anderson Cancer Center to investigate the clinical use of ANGLE's
Parsortix system as a companion diagnostic in colorectal
cancer.
The University of Texas MD Anderson Cancer Center is one of the
world's most respected centres devoted exclusively to cancer
patient care, research, education and prevention. MD Anderson was
created in 1941 as part of The University of Texas System. United
States News & World Report's "Best Hospitals" survey has ranked
MD Anderson as one of the nation's top two cancer centres every
year since the survey began in 1990. MD Anderson's Clinical Center
for Targeted Therapy is the largest programme in the world
expediting the development of new cancer drugs.
The research collaboration is being led by Drs. Mien-Chie Hung,
Vice President for Basic Research, and Chairman of the Department
of Molecular and Cellular Oncology, Scott Kopetz, Associate
Professor, GI Medical Oncology and Shulin Li, Professor,
Pediatrics, The University of Texas MD Anderson Cancer Center.
MD Anderson will recruit 50 metastatic colorectal cancer
patients for the patient study, which is expected to report by the
end of the year. Blood will be collected from each patient and
processed using ANGLE's Parsortix system. The harvested circulating
tumour cells (CTCs) will be distributed to three different MD
Anderson labs in pursuit of three key objectives:
-- Investigation of key markers on the CTCs, which may act as a
companion diagnostic to indicate which patients will benefit from
the Merck Serono's FDA approved drug Erbitux (Cetuximab). A
successful outcome may lead to the use of a Parsortix blood test to
help guide the treatment regime to be offered to colorectal cancer
patients.
-- Investigating the number of CTCs that have been through the
EMT (epithelial mesenchymal transition) phase and are involved in
the process of metastasis. Such mesenchymal CTCs cannot be
effectively detected by antibody systems and the capability of the
Parsortix system to harvest these CTCs for analysis may yield
important clinical information on the process of metastasis leading
to secondary cancers.
-- Investigation of the potential to develop the capability to
culture colorectal cancer CTCs harvested by the Parsortix system to
provide a population of the patient's cancer cells outside the
patient for investigation, for example for chemosensitivity
testing.
ANGLE is strongly focused on establishing the use of the
Parsortix system in clinical practice. To achieve this, a top
priority is the establishment of collaborations with key opinion
leaders at world class translational research centres. These key
opinion leaders are working to identify clinical applications with
medical utility (clear benefit to patients), and to obtain clinical
data that demonstrates that utility in patient studies. ANGLE
believes this is the optimal approach for unlocking the
multi-billion dollar worldwide market available to the Company and
its potential strategic partners. The first such translational
research patient study in ovarian cancer was completed by Medical
University of Vienna in January 2015 and reported "unprecedented
sensitivity and specificity". This is now being developed as a
clinical application for ovarian cancer.
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"We are delighted to be working with MD Anderson and Drs. Hung,
Kopetz and Li to develop clinical applications using the Parsortix
system as a companion diagnostic in the treatment of colorectal
cancer patients."
For further information:
ANGLE plc 01483 685830
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Cenkos Securities
Stephen Keys, Dr Christopher
Golden (Nominated adviser)
Russell Kerr, Oliver Baxendale
(Sales) 020 7397 8900
Buchanan
Mark Court, Sophie Cowles,
Jane Glover 020 7466 5000
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc
ANGLE is a specialist medtech company commercialising a platform
technology that can capture cells circulating in blood, such as
cancer cells, even when they are as rare in number as one cell in
one billion blood cells, and harvest the cells for analysis.
ANGLE's cell separation technology, known as the Parsortix
system, harvests the cells of interest through a liquid biopsy,
with the patient only experiencing a simple blood test. Parsortix
is the subject of two granted US patents and three extensive
families of patents being progressed worldwide. The system is based
on a microfluidic device that captures cells based on a combination
of their size and compressibility. The Parsortix system is
established with strong positive evaluations from leading cancer
research centres and is working with these cancer centres to
demonstrate key applications. Parsortix has a CE Mark for Europe
and FDA authorisation is in process for the US.
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The Parsortix system is designed to be compatible with existing
major medtech analytical platforms and to act as a companion
diagnostic for major pharmaceutical companies in helping to
identify patients that will benefit from a particular drug and then
monitoring the drug's effectiveness.
ANGLE has established formal collaborations with world-class
cancer centres and is working with these cancer centres to
demonstrate key applications for its Parsortix non-invasive cancer
diagnostic system as a liquid biopsy. Details are available here
http://www.angleplc.com/the-company/collaborators/
In addition to cancer, the Parsortix technology has the
potential for deployment with several other important cell types in
the future.
ANGLE began trading on the AIM market of the London Stock
Exchange in March 2004 under the ticker symbol AGL. For more
information visit www.angleplc.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRLFFFFFIIELIE
Angle (LSE:AGL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Angle (LSE:AGL)
Historical Stock Chart
From Sep 2023 to Sep 2024